Medicure Reports Financial Results for Quarter Ended June 30, 2024
Medicure Inc. (TSXV:MPH)(OTC PINK:MCUJF) reported financial results for Q2 2024. Total net revenue decreased to $5.2 million from $6.0 million in Q2 2023. AGGRASTAT sales declined to $1.8 million from $2.6 million. Marley Drug business revenue remained stable at $2.7 million. ZYPITAMAG sales increased slightly to $1.4 million from $1.3 million. The company reported a net loss of $1.2 million ($0.12 per share) compared to a net income of $253,000 ($0.03 per share) in Q2 2023. Adjusted EBITDA was negative $514,000, down from $948,000. Cash and cash equivalents stood at $5.9 million as of June 30, 2024.
Medicure Inc. (TSXV:MPH)(OTC PINK:MCUJF) ha riportato i risultati finanziari per il secondo trimestre del 2024. Il fatturato totale netto è diminuito a 5,2 milioni di dollari rispetto ai 6,0 milioni nel secondo trimestre del 2023. Le vendite di AGGRASTAT sono scese a 1,8 milioni di dollari, dai 2,6 milioni precedenti. Il fatturato del business Marley Drug è rimasto stabile a 2,7 milioni di dollari. Le vendite di ZYPITAMAG sono aumentate leggermente a 1,4 milioni di dollari, rispetto a 1,3 milioni. L'azienda ha riportato una perdita netta di 1,2 milioni di dollari (0,12 dollari per azione) rispetto a un guadagno netto di 253.000 dollari (0,03 dollari per azione) nel secondo trimestre del 2023. EBITDA rettificato è stato negativo per 514.000 dollari, in calo rispetto a 948.000 dollari. La liquidità e gli equivalenti di liquidità ammontavano a 5,9 milioni di dollari al 30 giugno 2024.
Medicure Inc. (TSXV:MPH)(OTC PINK:MCUJF) informó los resultados financieros del segundo trimestre de 2024. Los ingresos netos totales disminuyeron a 5.2 millones de dólares desde 6.0 millones en el segundo trimestre de 2023. Las ventas de AGGRASTAT cayeron a 1.8 millones de dólares desde 2.6 millones. Los ingresos del negocio Marley Drug se mantuvieron estables en 2.7 millones de dólares. Las ventas de ZYPITAMAG aumentaron ligeramente a 1.4 millones de dólares desde 1.3 millones. La compañía reportó una pérdida neta de 1.2 millones de dólares (0.12 dólares por acción) en comparación con un ingreso neto de 253,000 dólares (0.03 dólares por acción) en el segundo trimestre de 2023. El EBITDA ajustado fue negativo por 514,000 dólares, frente a 948,000 dólares. El efectivo y equivalentes de efectivo ascendían a 5.9 millones de dólares al 30 de junio de 2024.
Medicure Inc. (TSXV:MPH)(OTC PINK:MCUJF)는 2024년 2분기 재무 결과를 보고했습니다. 총 순수익은 2023년 2분기의 6.0백만 달러에서 5.2백만 달러로 감소했습니다. AGGRASTAT 판매는 2.6백만 달러에서 1.8백만 달러로 감소했습니다. Marley Drug 사업 수익은 2.7백만 달러로 안정적으로 유지되었습니다. ZYPITAMAG 판매는 1.3백만 달러에서 1.4백만 달러로 약간 상승했습니다. 이 회사는 2023년 2분기 253,000 달러 (주당 0.03 달러)의 순이익에 비해 1.2백만 달러 (주당 0.12 달러)의 순손실을 보고했습니다. 조정된 EBITDA는 -514,000 달러로, 이전의 948,000 달러에서 감소했습니다. 2024년 6월 30일 기준으로 현금 및 현금성 자산은 5.9백만 달러에 달했습니다.
Medicure Inc. (TSXV:MPH)(OTC PINK:MCUJF) a publié ses résultats financiers pour le deuxième trimestre de 2024. Le chiffre d'affaires net total a diminué à 5,2 millions de dollars contre 6,0 millions au deuxième trimestre 2023. Les ventes de AGGRASTAT ont chuté à 1,8 million de dollars contre 2,6 millions. Le chiffre d'affaires de l'activité Marley Drug est resté stable à 2,7 millions de dollars. Les ventes de ZYPITAMAG ont légèrement augmenté à 1,4 million de dollars, contre 1,3 million. L'entreprise a enregistré une perte nette de 1,2 million de dollars (0,12 dollar par action) comparativement à un revenu net de 253 000 dollars (0,03 dollar par action) au deuxième trimestre 2023. EBITDA ajusté était de -514 000 dollars, en baisse par rapport à 948 000 dollars. La trésorerie et équivalents de trésorerie s'élevaient à 5,9 millions de dollars au 30 juin 2024.
Medicure Inc. (TSXV:MPH)(OTC PINK:MCUJF) hat die finanziellen Ergebnisse für das 2. Quartal 2024 bekannt gegeben. Der Gesamtnettoertrag sank auf 5,2 Millionen Dollar von 6,0 Millionen im 2. Quartal 2023. Der Umsatz von AGGRASTAT fiel auf 1,8 Millionen Dollar von 2,6 Millionen. Der Umsatz des Geschäftsbereichs Marley Drug blieb stabil bei 2,7 Millionen Dollar. Der Umsatz von ZYPITAMAG stieg leicht auf 1,4 Millionen Dollar von 1,3 Millionen. Das Unternehmen meldete einen Nettoverlust von 1,2 Millionen Dollar (0,12 Dollar pro Aktie) im Vergleich zu einem Nettogewinn von 253.000 Dollar (0,03 Dollar pro Aktie) im 2. Quartal 2023. Bereinigtes EBITDA betrug -514.000 Dollar, ein Rückgang von 948.000 Dollar. Der Kassenstand und die liquiden Mittel beliefen sich am 30. Juni 2024 auf 5,9 Millionen Dollar.
- Marley Drug business revenue remained stable at $2.7 million
- ZYPITAMAG sales increased slightly to $1.4 million from $1.3 million
- The number of hospital customers using AGGRASTAT remains strong
- Total net revenue decreased to $5.2 million from $6.0 million in Q2 2023
- AGGRASTAT sales declined to $1.8 million from $2.6 million
- Net loss of $1.2 million compared to net income of $253,000 in Q2 2023
- Adjusted EBITDA was negative $514,000, down from $948,000
- Cash and cash equivalents decreased to $5.9 million from $6.4 million at the end of 2023
WINNIPEG, ON / ACCESSWIRE / August 14, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended June 30, 2024.
Quarter Ended June 30, 2024 Highlights:
Recorded total net revenue of
$5.2 million during the quarter ended June 30, 2024 compared to$6.0 million for the quarter ended June 30, 2023 and;Recorded total net revenue from the sale of AGGRASTAT® of
$1.8 million during the quarter ended June 30, 2024 compared to$2.6 million for the quarter ended June 30, 2023 and;Recorded total net revenue from the Marley Drug business of
$2.7 million ($790,000 from sales of ZYPITAMAG®, and$1.9 million from other pharmacy revenue) during the quarter ended June 30, 2024 compared to$2.7 million ($600,000 from sales of ZYPITAMAG and$2.1 million from other pharmacy revenue) for the quarter ended June 30, 2023 and;Recorded total net revenue from the sale of ZYPITAMAG of
$1.4 million ($654,000 t hrough the insured business, and$790,000 t hrough Marley Drug) during the quarter ended June 30, 2024 compared to$1.3 million ($722,000 t hrough insured business and$600,000 t hrough Marley Drug) for the quarter ended June 30, 2023 and;Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA1) for the quarter ended June 30, 2024 was negative
$514,000 compared to adjusted EBITDA of$948,000 for the quarter ended June 30, 2023 and;Net Loss for the quarter ended June 30, 2024 was
$1.2 million or$0.12 per share compared to net income of$253,000 or$0.03 per share for the quarter ended June 30, 2023.
Financial Results
The decrease in AGGRASTAT revenues when compared to the same period in the previous year, as described above, is the result of an increase in pricing competition from generic tirofiban hydrochloride in 2024 when compared to 2023. However, the number of hospital customers using AGGRASTAT continues to remain strong and the Company continues to work on maintaining its customer base and recovering any lost business.
The Marley Drug business contributed
ZYPITAMAG through insured channels contributed
Adjusted EBITDA for the quarter ended June 30, 2024 was negative
Net loss for the quarter ended June 30, 2024 was
At June 30, 2024, the Company had unrestricted cash totaling
All amounts referenced herein are in Canadian dollars unless otherwise noted.
The full financial statements are available at www.sedar.com and on the Company's website at www.medicure.com.
Notes
The Company defines EBITDA as "earnings before interest, taxes, depreciation and amortization" and Adjusted EBITDA as "EBITDA adjusted for non cash and non-recurring items". The terms "EBITDA" and "Adjusted EBITDA", as it relates to the three month period ended June 30, 2024 and 2023 results prepared using IFRS, do not have any standardized meaning according to IFRS.
Conference Call Info:
Topic: Medicure's Q2 2024 Results
Call date: Thursday, August 15, 2024
Time: 7:30 AM Central Time (8:30 AM Eastern Time)
Toll Free: 1 (877) 545-0523
International: 1 (973) 528-0016
Participant Access Code: 723143
Webcast: This conference call will be webcast live over the internet at the following link: https://www.webcaster4.com/Webcast/Page/2965/51066
You may request international country-specific access information by e-mailing the Company in advance. Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call. A recording of the call will be available following the event at the Company's website.
About Medicure Inc.
Medicure is a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug Inc. ("Marley Drug"), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug® is committed to improving access to medications for all Americans together with exceptional customer service and free home delivery. For more information visit www.marleydrug.com . For more information about Medicure please visit www.medicure.com. For additional information about AGGRASTAT®, please visit www.aggrastat.com or refer to the full Prescribing Information. For additional information about ZYPITAMAG®, please visit www.zypitamag.com or refer to the full Prescribing Information.
To be added to Medicure's e-mail list, please visit:
http://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's future product revenues, expected results, including future revenue from P5P, the likelihood of receiving a priority review voucher from the United State Food and Drug Administration, expected future growth in revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk Factors" section of its current Form 20F.
AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAG® (pitavastatin) tablets, and Marley Drug® are registered trademarks.
For more information, please contact:
Dr. Albert D. Friesen
Chief Executive Officer
Tel. 888-435-2220
Fax 204-488-9823
E-mail: info@medicure.com
www.medicure.com
Consolidated Statements of Financial Position
(expressed in thousands of Canadian dollars, except per share amounts)
| June 30, 2024 |
|
| December 31, 2023 |
| |||
Assets |
|
|
|
|
|
| ||
Current assets: |
|
|
|
|
|
| ||
Cash and cash equivalents |
| $ | 5,850 |
|
| $ | 6,369 |
|
Accounts receivable |
|
| 4,478 |
|
|
| 4,794 |
|
Inventories |
|
| 3,816 |
|
|
| 2,900 |
|
Prepaid expenses |
|
| 1,726 |
|
|
| 1,143 |
|
Total current assets |
|
| 15,870 |
|
|
| 15,206 |
|
Non-current assets: |
|
|
|
|
|
|
|
|
Property and equipment |
|
| 539 |
|
|
| 736 |
|
Intangible assets |
|
| 8,539 |
|
|
| 8,940 |
|
Goodwill |
|
| 3,210 |
|
|
| 3,102 |
|
Other assets |
|
| 78 |
|
|
| 75 |
|
Total non-current assets |
|
| 12,366 |
|
|
| 12,853 |
|
Total assets |
| $ | 28,236 |
|
| $ | 28,059 |
|
Liabilities and Equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities |
| $ | 8,222 |
|
| $ | 7,603 |
|
Income taxes payable |
|
| 71 |
|
|
| 16 |
|
Current portion of lease obligations |
|
| 215 |
|
|
| 315 |
|
Total current liabilities |
|
| 8,508 |
|
|
| 7,934 |
|
Non-current liabilities |
|
|
|
|
|
|
|
|
Lease obligations |
|
| 187 |
|
|
| 229 |
|
Total non-current liabilities |
|
| 187 |
|
|
| 229 |
|
Total liabilities |
|
| 8,695 |
|
|
| 8,163 |
|
Equity: |
|
|
|
|
|
|
|
|
Share capital |
|
| 81,014 |
|
|
| 81,014 |
|
Contributed surplus |
|
| 10,823 |
|
|
| 10,723 |
|
Accumulated other comprehensive loss |
|
| (5,278 | ) |
|
| (5,989 | ) |
Deficit |
|
| (67,018 | ) |
|
| (65,852 | ) |
Total equity |
|
| 19,541 |
|
|
| 19,896 |
|
Total liabilities and equity |
| $ | 28,236 |
|
| $ | 28,059 |
|
Consolidated Statements of Net Income and Comprehensive Income
(expressed in thousands of Canadian dollars, except per share amounts)
| Three months ended June 30, 2024 |
|
| Three months ended June 30, 2023 |
|
| Six months ended June 30, 2024 |
|
| Six months ended June 30, 2023 |
| |||||
|
|
|
|
|
|
|
|
|
|
|
| |||||
Revenue, net |
| $ | 5,165 |
|
| $ | 5,993 |
|
| $ | 10,859 |
|
| $ | 11,621 |
|
Cost of goods sold |
|
| 2,213 |
|
|
| 1,805 |
|
|
| 4,010 |
|
|
| 3,637 |
|
Gross profit |
|
| 2,952 |
|
|
| 4,188 |
|
|
| 6,849 |
|
|
| 7,984 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling |
|
| 1,834 |
|
|
| 2,068 |
|
|
| 3,808 |
|
|
| 4,106 |
|
General and administrative |
|
| 1,368 |
|
|
| 1,125 |
|
|
| 2,577 |
|
|
| 2,032 |
|
Research and development |
|
| 868 |
|
|
| 668 |
|
|
| 1,544 |
|
|
| 1,194 |
|
|
| 4,070 |
|
|
| 3,861 |
|
|
| 7,929 |
|
|
| 7,332 |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Finance (income) costs: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Finance (income) expense, net |
|
| (36 | ) |
|
| (22 | ) |
|
| (87 | ) |
|
| (17 | ) |
Foreign exchange (gain) loss, net |
|
| 25 |
|
|
| 30 |
|
|
| 32 |
|
|
| 54 |
|
|
| (11 | ) |
|
| 8 |
|
|
| (55 | ) |
|
| 37 |
| |
Net income (loss) before income taxes |
| $ | (1,107 | ) |
| $ | 319 |
|
| $ | (1,025 | ) |
| $ | 615 |
|
Income tax expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current |
|
| 110 |
|
|
| 66 |
|
|
| 141 |
|
|
| 73 |
|
Net income (loss) |
| $ | (1,217 | ) |
| $ | 253 |
|
| $ | (1,166 | ) |
| $ | 542 |
|
Other comprehensive income (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Item that may be reclassified to profit or loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exchange differences on translation of foreign subsidiaries |
|
| 212 |
|
|
| (463 | ) |
|
| 711 |
|
|
| (488 | ) |
Other comprehensive income (loss), net of tax |
|
| 212 |
|
|
| (463 | ) |
|
| 711 |
|
|
| (488 | ) |
Comprehensive income (loss) |
| $ | (1,005 | ) |
| $ | (210 | ) |
| $ | (455 | ) |
| $ | 54 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Earnings (loss) per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
| $ | (0.12 | ) |
| $ | 0.02 |
|
| $ | (0.11 | ) |
| $ | 0.05 |
|
Diluted |
| $ | (0.12 | ) |
| $ | 0.02 |
|
| $ | (0.11 | ) |
| $ | 0.05 |
|
Consolidated Statements of Cash Flows
(expressed in thousands of Canadian dollars, except per share amounts)
For the six months ended June 30 |
| 2024 |
|
| 2023 |
| ||
Cash (used in) provided by: |
|
|
|
|
|
| ||
Operating activities: |
|
|
|
|
|
| ||
Net income (loss) for the period |
| $ | (1,166 | ) |
| $ | 542 |
|
Adjustments for: |
|
|
|
|
|
|
|
|
Amortization of property, plant and equipment |
|
| 209 |
|
|
| 224 |
|
Amortization of intangible assets |
|
| 897 |
|
|
| 866 |
|
Share-based compensation |
|
| 100 |
|
|
| 130 |
|
Finance income, net |
|
| (87 | ) |
|
| (17 | ) |
Unrealized foreign exchange (gain) loss |
|
| 32 |
|
|
| 54 |
|
Income tax expense |
|
| 141 |
|
|
| 66 |
|
Change in the following: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
| 336 |
|
|
| (138 | ) |
Inventories |
|
| (870 | ) |
|
| (65 | ) |
Prepaid expenses |
|
| (465 | ) |
|
| (174 | ) |
Accounts payable and accrued liabilities |
|
| 650 |
|
|
| (498 | ) |
Other assets |
|
| - |
|
|
| - |
|
Interest received (paid), net |
|
| 115 |
|
|
| - |
|
Income taxes paid |
|
| (54 | ) |
|
| (105 | ) |
Royalties paid |
|
| - |
|
|
| (119 | ) |
Cash flows from (used in) operating activities |
|
| (162 | ) |
|
| 766 |
|
Investing activities: |
|
|
|
|
|
|
|
|
Acquisition of intangible assets |
|
| (191 | ) |
|
| (27 | ) |
Cash flows used in investing activities |
|
| (191 | ) |
|
| (27 | ) |
Financing activities: |
|
|
|
|
|
|
|
|
Repayment of lease liability |
|
| (166 | ) |
|
| (151 | ) |
Cash flows used in financing activities |
|
| (166 | ) |
|
| (151 | ) |
Increase in cash and cash equivalents |
|
| (519 | ) |
|
| 588 |
|
Cash and cash equivalents, beginning of period |
|
| 6,369 |
|
|
| 4,857 |
|
Cash and cash equivalents, end of period |
| $ | 5,850 |
|
| $ | 5,445 |
|
SOURCE: Medicure, Inc.
View the original press release on accesswire.com
FAQ
What was Medicure's total net revenue for Q2 2024?
How did AGGRASTAT sales perform in Q2 2024 for Medicure (MCUJF)?
What was Medicure's (MCUJF) net income/loss for Q2 2024?